glp-1 cv outcome trials GLP1 agonists: current and future landscape of clinical for patients with metabolic dysfunction SELECT Trial

The association between impulsivity and violent behavior was about 62% weaker among current users compared with former users

Note: material may have been edited for length and content

Notably, this suggests the drug enhances the mechanisms that signal fullness, rather than suppressing hunger

Think about whether your prescribing provider can advocate for you if there are problems

Semaglutide delivers significant weight loss averaging 15-17% of body weight, improved cardiovascular health markers, enhanced glycemic control, reduced appetite, and sustained weight maintenance over extended periods

Among patients with Type 2 diabetes, weight reduction averaged only 23% after 72 weeks